We report a patient harboring a novel homozygous mutation of c.604T > G (p.F202V) in POMT2. He showed delayed psychomotor development but acquired the ability to walk at the age of 3 years and 10 months. His brain MRI was normal. No ocular abnormalities were seen. Biopsied skeletal muscle revealed markedly decreased but still detectable glycosylated forms of alpha-dystroglycan (a-DG). Our results indicate that mutations in POMT2 can cause a wide spectrum of clinical phenotypes as observed in other genes associated with a-dystroglycanopathy. Presence of small amounts of partly glycosylated a-DG may have a role in reducing the clinical symptoms of a-dystroglycanopathy.
Introduction
Alpha-dystroglycan (a-DG) is a surface membrane protein that links extracellular basal lamina and intracellular cytoskeleton. a-DG is a highly glycosylated protein mainly composed of unique O-mannosyl glycans. Reduced/altered glycosylation of a-DG causes a wide variety of muscular dystrophies including Walker-Warburg syndrome (WWS), muscle-eye-brain disease (MEB), Fukuyama-type congenital muscular dystrophy (FCMD), congenital muscular dystrophies type 1C and type 1D, and limb girdle muscular dystrophies (LGMD) type 2I, 2K to 2N. They are collectively called alpha-dystroglycanopathies (a-DGP). So far, six causative genes for a-DGP have been identified including protein-O-mannosyl transferase 1 and 2 (POMT1 and POMT2), protein O-mannose b-1,2-N-acetylglucosaminyltransferase (POMGnT1), fukutin (FKTN), fukutin-related protein (FKRP), and acetylglucosaminyl transferase-like protein (LARGE). Here we report a mild congenital muscular dystrophy patient associated with a novel homozygous mutation in POMT2.
Case report
A 4-year-old Japanese boy, the only child from healthy consanguineous parents, was delivered uneventfully at full term. During few days after birth, he was 
